Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer

Conditions:Colorectal Cancer, Cancer
Therapuetic Areas:Oncology
Age Range:18 - Any
Start Date:March 2010
End Date:July 2013

Use our guide to learn which trials are right for you!

The purpose of this study is to determine if positron emission tomography (PET) imaging with
an imaging agent called 18F-fluorodeoxythymidine([18F]-FLT) will allow investigators to
measure how well tumor(s) respond to treatment without taking a tissue sample (biopsy).
Additionally, the investigators want to determine if it is possible to predict how well
tumor(s) might respond to treatment with [18F]-FLT PET imaging.

Inclusion Criteria:

- Subjects with known rectal cancer.

- Subjects must have signed an approved consent form.

- Subjects must be 18 years of age or older.

Exclusion Criteria:

- Children less than 18 are excluded.

- Pregnant women and women who are breast feeding will be excluded from this study. A
serum beta HCG will also be performed for each pre-menopausal female subject.

- Patients who are acutely ill who are deemed by their treating physician as not
suitable candidates for this study
We found this trial at
2220 Pierce Ave
Nashville, Tennessee 37232
Vanderbilt-Ingram Cancer Center The Vanderbilt-Ingram Cancer Center, located in Nashville, Tenn., brings together the clinical...
Nashville, TN
Click here to add this to my saved trials